Endoscopic resection for gastric subepithelial tumours: a retrospective cohort study

胃黏膜下肿瘤的内镜切除术:一项回顾性队列研究

阅读:1

Abstract

OBJECTIVE: Although endoscopic resection (ER) is an established technique for gastric subepithelial tumours (SETs), comprehensive data on its efficacy and safety remain limited. This study aimed to evaluate the efficacy and safety of ER in patients with gastric SETs and to identify risk factors associated with procedure-related complications. MATERIALS AND METHODS: This retrospective study included 483 patients who underwent ER for gastric SETs between February 2012 and May 2023. Patient demographics, tumour characteristics, and clinical outcomes were evaluated. Multivariate analysis was performed to identify risk factors for complications. RESULTS: The median tumour size was 1.2 cm (range: 0.5-6.0 cm). The complete resection rate was 93.8%. Complications occurred in 6.8% of cases, including perioperative bleeding (2.1%), perforation (1.7%), and both (0.4%), with 0.8% of cases requiring conversion to surgery. Larger tumours notably increased the risks of incomplete resection (odds ratio [OR] = 1.605, 95% confidence interval [CI]: 1.066-2.416, p = 0.023), perioperative bleeding (OR = 2.004, 95% CI: 1.099-3.653, p = 0.023), and perforation (OR = 3.476, 95% CI: 1.830-6.602, p < 0.001). Additionally, an irregular tumour shape significantly elevated the risk of incomplete resection (OR = 10.771, 95% CI: 3.452-33.605, p < 0.001). Conversely, tumours located in the middle third (OR = 0.068, 95% CI: 0.014-0.341, p = 0.001) and the upper third (OR = 0.211, 95% CI: 0.051-0.884, p = 0.033) of the stomach substantially reduced the risk of incomplete resection. CONCLUSIONS: ER is an effective and generally safe treatment modality for managing gastric SETs. However, larger tumour size and irregular shape are significant risk factors for adverse outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。